This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
generalized-anxiety-disorder
Generalized Anxiety Disorder
GAD (6% lifetime prevalence) is defined by 6+ months of excessive, uncontrollable worry; driven by HPA axis dysregulation, noradrenergic hyperactivity, and GABAergic deficit; SSRIs/SNRIs and duloxetine are first-line; buspirone and pregabalin are alternatives.
Entry Metadata
| Field | Value |
|---|---|
| ID | generalized-anxiety-disorder |
| Name | Generalized Anxiety Disorder |
| Status | draft |
| Last reviewed | 2026-06-08 |
| Atlas | 01-human |
| Scale | 07-system |
Cross-Atlas Connections
Sources
- Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593-602. · PubMed 15939837
- Bandelow B, Michaelis S. Epidemiology of anxiety disorders in the 21st century. Dialogues Clin Neurosci. 2015;17(3):327-335. · PubMed 26487812
- Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28(5):403-439. · PubMed 24713617